Literature DB >> 2428377

Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates.

D G Kennedy, H W Van den Berg, R Clarke, R F Murphy.   

Abstract

MTX and dipyridamole are synergistic in their toxicity towards the MDA.MB.436 human breast cancer cell line. Dipyridamole increases net MTX uptake into the cells and increases the intracellular levels of MTXG7 to G10, the highest molecular weight polyglutamyl derivatives of MTX detected. During a recovery period, after completion of exposure to MTX with and without dipyridamole, levels of MTXG7 to G10 remained elevated in dipyridamole treated cells by comparison with controls. Dipyridamole, which has no intrinsic effect on cell growth, transforms a cytostatic response of MDA.MB.436 cells towards MTX into a cytotoxic response. The effect of dipyridamole is not mediated through an increase in prostacyclin biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428377     DOI: 10.1016/0006-2952(86)90385-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Dipyridamole prevents triple-negative breast-cancer progression.

Authors:  Daniela Spano; Jean-Claude Marshall; Natascia Marino; Daniela De Martino; Alessia Romano; Maria Nunzia Scoppettuolo; Anna Maria Bello; Valeria Di Dato; Luigi Navas; Gennaro De Vita; Chiara Medaglia; Patricia S Steeg; Massimo Zollo
Journal:  Clin Exp Metastasis       Date:  2012-07-04       Impact factor: 5.150

3.  Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.

Authors:  R Goel; R Sanga; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Nicaraven prevents the fast growth of inflamed tumors by an anti-inflammatory mechanism.

Authors:  Lina Abdelghany; Xu Zhang; Tsuyoshi Kawabata; Shinji Goto; Nageh El-Mahdy; Keiichi Jingu; Tao-Sheng Li
Journal:  Med Oncol       Date:  2021-11-10       Impact factor: 3.064

5.  Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

Authors:  Ahmed E Goda; Raymond L Erikson; Toshiyuki Sakai; Jong-Seog Ahn; Bo-Yeon Kim
Journal:  Mol Oncol       Date:  2014-09-06       Impact factor: 6.603

Review 6.  Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.

Authors:  A R Kinsella; D Smith; M Pickard
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Dipyridamole induces the phosphorylation of CREB to promote cancer cell proliferation.

Authors:  Lina Abdelghany; Nageh El-Mahdy; Tsuyoshi Kawabata; Shinji Goto; Tao-Sheng Li
Journal:  Oncol Lett       Date:  2021-02-03       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.